Efforts to Control Prescription Drug Pricing Harm Collaborative Work to Advance Patient Care with Health Innovations

Elyse Blazevich, President & CEO, Colorado BioScience Association Colorado’s life sciences community and our state leaders share an unwavering commitment to improving patient lives and making sure...

Learn More

Weekly Policy Blog: FDA Guidances on 510(k) Submissions; Actuarial Review of Biomarker Testing Coverage Bill 

FDA Issues Three Guidances on Premarket Notification [510(k)] Program  On September 7, 2023, the U.S. Food and Drug Administration’s (FDA’s) Center for Devices and Radiological Health (CDRH) issu...

Learn More

Weekly Policy Blog: CMS Announces Drugs Subject to Price Controls Under the IRA 

On August 29, 2023, the Centers for Medicare and Medicaid Services (CMS) announced the first ten prescription drugs that will be subject to price controls in Medicare under the Inflation Reduction Act...

Learn More

Weekly Policy Blog: CBSA and Partners Provide Recommendations to Improve CMS’ Transitional Coverage for Emerging Technologies (TCET) Proposal 

CBSA advocates for policies that improve patient access to life-saving novel technologies. This week, CBSA signed on to a letter responding to the long-awaited proposed Transitional Coverage for Emerg...

Learn More

Weekly Policy Blog: PDAB Releases Stakeholder Engagement Guide on Affordability Review Process

As the Colorado Prescription Drug Affordability Board (PDAB) begins affordability reviews of the five prescription drugs selected earlier this month, it is reaching out to stakeholders to request thei...

Learn More

Weekly Policy Blog: PDAB Selects Drugs for Affordability Reviews

On Friday, August 4, the Colorado Prescription Drug Affordability Board (PDAB) selected five drugs for affordability reviews: Enbrel, Genvoya, Cosentyx, Stelara, and Trikafta. PDAB staff plan to begin...

Learn More

Weekly Policy Blog: Congressional Activity Before August Recess

Congress moved forward with its efforts to address drug shortages, drug pricing, pharmacy benefit managers (PBMs), and transparency ahead of the August recess. This policy post covers the discussion d...

Learn More

Weekly Policy Blog: PAHPA Reauthorization Advances Without Government Price Fixing

Congress took important action on pandemic preparedness last week, advancing the Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization bills in both the Senate and the House ahead of its e...

Learn More

Weekly Policy Blog: Drug Pricing and Affordability Update

Drug pricing and affordability continue to be key issues at both the state and federal levels as new legislation is considered and implementation of legislation that has already passed is underway....

Learn More

Weekly Policy Blog: Ethylene Oxide – EPA’s Proposed Rules 

Ethylene Oxide (EtO or EO) is a colorless gas used commercially in a wide variety of ways. It is one of the most common and proven ways to sterilize medical devices. EtO’s proven effectiveness means t...

Learn More